Andrii Bidochko

• Updated: April 2, 2026
• 5 min read

Medvi’s AI‑Driven Telehealth Startup Hits $1.8 Billion in Sales

Medvi, the Los‑Angeles‑based telehealth startup founded by Matthew Gallagher, has just been valued at **$1 billion** after a rapid AI‑driven growth trajectory that generated $401 million in sales in its first full year and is on track for $1.8 billion this year.

Medvi’s $1 Billion AI Valuation: How a Two‑Person Team Disrupted Telehealth

In a market where traditional health‑tech firms spend millions on staff, data pipelines, and compliance, Medvi proved that a lean AI‑first approach can create a billion‑dollar company with just two full‑time employees. The valuation, announced on April 2 2026, marks a watershed moment for AI‑enabled startups and signals a new era for investors, healthcare entrepreneurs, and AI enthusiasts alike.

Who Is Medvi and Its Founder?

Medvi is a telehealth platform that prescribes GLP‑1 weight‑loss medications, combining clinical oversight with a fully automated customer journey. The company was launched by Matthew Gallagher, a 41‑year‑old serial entrepreneur who previously built several SaaS tools. Gallagher’s vision was simple: let artificial intelligence handle everything that does not require a human touch.

Founder Matthew Gallagher’s AI‑First Playbook

Gallagher invested just $20,000 and two months of his time to assemble a toolbox of more than a dozen AI services. From code generation to copywriting, from image creation to real‑time analytics, each component was powered by generative models. He even outsourced the few tasks that AI could not yet master to freelancers, keeping the core team to himself and his younger brother, Elliot, who joined as the sole employee in 2025.

How AI Powered Medvi’s Explosive Growth

AI‑Generated Code, Content, and Customer Service

Using the OpenAI ChatGPT integration, Gallagher wrote the entire backend in under a week. The same model produced landing‑page copy, ad creatives, and even the FAQ chatbot that handles 95% of patient inquiries without human intervention. For voice‑based interactions, Medvi leveraged the ElevenLabs AI voice integration, turning text prompts into natural‑sounding conversations that guide patients through prescription onboarding.

AI‑Driven Analytics and Decision‑Making

Medvi’s growth engine is powered by a Chroma DB integration that stores vector embeddings of every user interaction. This enables real‑time cohort analysis, churn prediction, and dynamic pricing adjustments. The platform’s Workflow automation studio stitches together data pipelines, automatically triggering marketing campaigns when a new patient completes a health questionnaire.

Financial Milestones and Market Impact

The numbers tell a compelling story of AI‑enabled scalability:

• First month: 300 paying patients acquired solely through AI‑generated ads.
• Second month: +1,000 new patients, a 333% month‑over‑month growth.
• 2025 (first full year): $401 million in gross sales.
• 2026 (projected): $1.8 billion in sales, a 350% increase YoY.
• Current headcount: 2 full‑time employees, plus a handful of part‑time contractors.

The $1 billion valuation was derived from a recent Series B round led by UBOS partner program investors, who cited the company’s “unprecedented AI efficiency” as a key differentiator. Analysts predict that Medvi’s model will inspire a wave of AI‑first health‑tech ventures, reshaping how capital is allocated in the sector.

What the New York Times Says

“Medvi’s $1 billion valuation would have been unimaginable a decade ago, but with AI handling everything from code to customer support, the company has turned a $20,000 experiment into a multi‑billion‑dollar enterprise.” – The New York Times

Visualizing Medvi’s Journey

UBOS Solutions That Empower AI‑First Startups

Entrepreneurs looking to replicate Medvi’s success can tap into a suite of UBOS tools designed for rapid AI integration:

• AI marketing agents that auto‑generate ad copy and optimize spend.
• Enterprise AI platform by UBOS for secure, scalable model deployment.
• Web app editor on UBOS for drag‑and‑drop UI creation without writing a line of code.
• UBOS templates for quick start, including the “AI Article Copywriter” and “AI SEO Analyzer” templates.
• UBOS for startups offers a low‑cost entry tier with built‑in analytics.
• UBOS solutions for SMBs that combine CRM, chatbot, and voice AI in one dashboard.
• UBOS partner program provides co‑selling and technical enablement for AI‑centric ventures.
• UBOS pricing plans are transparent, with a pay‑as‑you‑grow model that aligns with early‑stage cash flow.

Template Marketplace Highlights

The UBOS marketplace also hosts ready‑made AI applications that can accelerate product launch:

• AI SEO Analyzer – instantly audits site health and suggests rank‑boosting changes.
• AI Chatbot template – a plug‑and‑play conversational agent for customer support.
• GPT‑Powered Telegram Bot – integrates ChatGPT with Telegram for real‑time user engagement.
• AI Video Generator – creates marketing videos from text scripts in minutes.

What This Means for Investors and Healthcare Entrepreneurs

Medvi’s valuation underscores three strategic takeaways:

1. AI efficiency translates directly to valuation. Investors are rewarding startups that can scale revenue with minimal headcount.
2. Regulated sectors are not immune to disruption. Telehealth, pharma, and insurance can all benefit from AI‑driven automation.
3. Platform ecosystems matter. Leveraging a robust AI platform—like the UBOS platform overview—reduces time‑to‑market and operational risk.

For venture capitalists, the lesson is clear: look beyond traditional metrics and assess a startup’s AI stack, data strategy, and automation maturity. For founders, the path forward involves building a modular AI architecture that can evolve as models improve.

Conclusion

Medvi’s $1 billion AI valuation proves that a disciplined, AI‑first approach can turn a modest $20,000 experiment into a multi‑billion‑dollar enterprise with just two employees. The company’s story is a blueprint for the next generation of health‑tech innovators and a signal to investors that AI efficiency is now a core valuation driver.

Ready to explore how AI can accelerate your own venture? Dive deeper into the latest AI‑driven news, case studies, and platform updates at UBOS news.

Andrii Bidochko

CTO UBOS

Andrii Bidochko is an AI entrepreneur and researcher focused on AI agents, reinforcement learning, and autonomous systems. He writes about the technologies shaping the future of machine intelligence, from frontier models and agent architectures to real-world AI applications.